Skip to main content

FUNCIÓN DEL CICLO CELULAR EN LA FORMACIÓN DE CÉLULAS MADRE PLURIPOTENTES INDUCIDAS PARA TERAPIA CELULAR EN MEDICINA REGENERATIVA.

RYC-2010-06512

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Contratación e Incorporación de RRHH
Subprogram Subprograma Ramón y Cajal (RYC)
Call Ramón y Cajal
Call year 2010
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Formación e Incorporación de Investigadores
Beneficiary centre FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

FUNCIÓN DEL CICLO CELULAR EN LA FORMACIÓN DE CÉLULAS MADRE PLURIPOTENTES INDUCIDAS PARA TERAPIA CELULAR EN MEDICINA REGENERATIVA.

RYC-2010-06512

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Contratación e Incorporación de RRHH
Subprogram Subprograma Ramón y Cajal (RYC)
Call Ramón y Cajal
Call year 2010
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Formación e Incorporación de Investigadores
Beneficiary centre UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The power and the promise of cell reprogramming, personalized autologous body organ and cell transplantation

  • Álvarez Palomo, Belén|||0000-0002-3894-044X
  • Lucas, Michaela|||0000-0001-8881-9990
  • Dilley, Rodney J.
  • McLenachan, Samuel
  • Chen, Fred Kuanfu
  • Requena, Jordi
  • Sal, Marti Farrera
  • Lucas, Andrew
  • Álvarez Pérez, Iñaki|||0000-0001-9484-0868
  • Jaraquemada, Dolores|||0000-0003-3328-740X
  • Edel, Michael J.|||0000-0002-5619-8680
Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Induced pluripotent stem cell-derived lung alveolar epithelial type II cells reduce damage in bleomycin-induced lung fibrosis

  • Álvarez Palomo, Belén|||0000-0002-3894-044X
  • Sanchez-Lopez, Luis Ignacio
  • Moodley, Yuben
  • Edel, Michael J.|||0000-0002-5619-8680
  • Serrano-Mollar, Anna|||0000-0002-4990-8162
Idiopathic pulmonary fibrosis is a chronic, progressive, and severe disease with a limited response to currently available therapies. Epithelial cell injury and failure of appropriate healing or regeneration are central to the pathogenesis of idiopathic pulmonary fibrosis. The purpose of this study is to investigate whether intratracheal transplantation of alveolar type II-like cells differentiated from induced pluripotent stem cells can stop and reverse the fibrotic process in an experimental model of bleomycin-induced lung fibrosis in rats. Human induced pluripotent stem cells were differentiated to alveolar type II-like cells and characterized. Lung fibrosis was induced in rats by a single intratracheal instillation of bleomycin. Animals were transplanted with human induced pluripotent stem cells differentiated to alveolar type II-like cells at a dose of 3 × 10 6 cells/animal 15 days after endotracheal bleomycin instillation when the animal lungs were already fibrotic. Animals were sacrificed 21 days after the induction of lung fibrosis. Lung fibrosis was assessed by hydroxiprolin content, histologic studies, and the expression of transforming growth factor-β and α-smooth muscle actin. Cell transplantation of alveolar type II-like cells differentiated from induced pluripotent stem cells can significantly reduce pulmonary fibrosis and improve lung alveolar structure, once fibrosis has already formed. This is associated with the inhibition of transforming growth factor-β and α-smooth muscle actin in the damaged rat lung tissue. To our knowledge, this is the first data to demonstrate that at the fibrotic stage of the disease, intratracheal transplantation of human induced pluripotent differentiated to alveolar type II-like cells halts and reverses fibrosis.